MedTrace Logo

A Trial of the ALK Grass Tablet in Subjects With Hayfever

NCT00227279 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 634

Last updated 2013-01-29

No results posted yet for this study

Summary

This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).

Conditions

  • Allergy

Interventions

BIOLOGICAL

ALK Grass tablet

Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Bente Tholstrup, MSc · ALK-Abello A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00227279 on ClinicalTrials.gov